- Home
- DHT vs VRDN Comparison
DHT vs VRDN Comparison
Compare DHT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHT | VRDN |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DHT | VRDN |
|---|---|---|
| Price | $18.41 | $19.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $16.33 | ★ $38.25 |
| AVG Volume (30 Days) | ★ 5.2M | 1.8M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $8.85 | $27.65 |
| Revenue Next Year | N/A | $253.29 |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.00 | $9.90 |
| 52 Week High | $20.55 | $34.29 |
Technical Indicators
Market Signals| Indicator | DHT | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 24.17 |
| Support Level | $10.85 | $17.91 |
| Resistance Level | $20.55 | $19.42 |
| Average True Range (ATR) | 0.70 | 1.11 |
| MACD | -0.02 | -1.00 |
| Stochastic Oscillator | 97.37 | 16.44 |
Price Performance
Historical ComparisonAbout DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. The company's primary business is operating a fleet of crude oil tankers, with a secondary activity of providing technical management services. Its fleet trades internationally and consists of VLCC crude oil tankers. The group generates revenues from time charter and spot market operations. It operates vessels through its subsidiary management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from Voyage charter revenues.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).